HC Wainwright Has Positive Estimate for DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities researchers at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Dynavax Technologies in a research report issued on Friday, November 8th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will post earnings of $0.18 per share for the year, up from their previous forecast of $0.17. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.18 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.04 EPS and FY2025 earnings at $0.26 EPS.

Separately, The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th.

Dynavax Technologies Stock Performance

Shares of DVAX opened at $13.50 on Monday. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $15.01. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35. The company has a market cap of $1.77 billion, a PE ratio of 104.00 and a beta of 1.34. The stock has a 50-day moving average price of $11.21 and a 200-day moving average price of $11.26.

Hedge Funds Weigh In On Dynavax Technologies

Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Dynavax Technologies by 1.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,172 shares in the last quarter. SummerHaven Investment Management LLC raised its stake in shares of Dynavax Technologies by 2.4% during the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 1,303 shares in the last quarter. Texas Permanent School Fund Corp lifted its holdings in shares of Dynavax Technologies by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after acquiring an additional 1,467 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.